Valuation: Satellos Bioscience Inc.

Market Cap 19Cr 16Cr 16Cr 14Cr 26Cr 1.79TCr 27Cr 185.74Cr 72Cr 913.66Cr 70Cr 69Cr 2.94TCr P/E 2026 *
-4.22x
P/E 2027 * -5.65x
Enterprise Value 8.49Cr 7.47Cr 7.06Cr 6.41Cr 12Cr 815.25Cr 12Cr 85Cr 33Cr 416Cr 32Cr 31Cr 1.34TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.36%
1 week-3.22%
Current month-4.27%
1 month+2.85%
3 months+22.11%
6 months+44.66%
Current year+57.26%
1 week 11.97
Extreme 11.97
12.75
1 month 11.97
Extreme 11.97
14.34
Current year 7.67
Extreme 7.67
18.98
1 year 7.56
Extreme 7.560003
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
20.28
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-3.22%+57.26%+130.65% 19Cr
-0.37%-3.67%+57.21%+87.75% 7.18TCr
+0.95%-0.28%+39.56%+85.19% 6.01TCr
+0.19%+1.61%+35.10%+17.20% 2.79TCr
-0.14%-2.75%-14.13%+356.79% 2.57TCr
+0.57%+1.10%+1.02%-2.89% 2.49TCr
+0.48%+1.27%+25.98%-7.97% 2.09TCr
-1.70%+0.43%+150.24%+323.16% 1.5TCr
+0.36%+2.01%+49.51%+160.70% 1.45TCr
+3.91%-3.51%-4.56%+517.49% 1.39TCr
Average +0.39%-1.69%+39.72%+166.81% 2.75TCr
Weighted average by Cap. +0.34%-1.91%+38.54%+128.11%

Financials

2026 *2027 *
Net sales - -
Net income -4.97Cr -4.37Cr -4.14Cr -3.75Cr -7.05Cr -477.45Cr -7.09Cr -50Cr -19Cr -243.63Cr -19Cr -18Cr -782.91Cr -6.11Cr -5.38Cr -5.09Cr -4.61Cr -8.66Cr -586.98Cr -8.71Cr -61Cr -24Cr -299.52Cr -23Cr -22Cr -962.5Cr
Net Debt -10Cr -8.94Cr -8.45Cr -7.66Cr -14Cr -975.27Cr -14Cr -101.17Cr -39Cr -497.66Cr -38Cr -37Cr -1.6TCr -12Cr -10Cr -9.9Cr -8.98Cr -17Cr -1.14TCr -17Cr -118.5Cr -46Cr -582.89Cr -45Cr -44Cr -1.87TCr
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
28/26/28 CA$12.46 -0.36% 3,047
25/26/25 CA$12.50 +1.30% 1,746
24/26/24 CA$12.34 +1.40% 9,615
23/26/23 CA$12.17 -4.02% 17,458
22/26/22 CA$12.68 -1.48% 5,730
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.46CAD
Average target price
17.47CAD
Spread / Average Target
+40.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock